IMMUNOCHEMISTRY OF GONOCOCCAL LIPOOLIGOSACCHARIDE
淋球菌低聚脂糖的免疫化学
基本信息
- 批准号:7369071
- 负责人:
- 金额:$ 0.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-01 至 2007-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project continues studies of how liooligosaccharide (LOS) mimicry of human glycosphingolipids (GSL) enables the transmission of Neisseria gonorrhoeae in order to find ways to prevent it. LOW are outer membrane glycolipids that have a glycose moiety that consists of proximal Basal Region and three short distal chains, termed _, _, and _. Many _ chain oligosaccharides are structurally identical to those of lacto- (Lac-R), globo- (P_(Gb3) and P1), paraglobo- (lacto-N-neotetraose (LNnT)), and gangliosyl (GalNAc_1-LNnT) series GSL. LOS are involved in attachment to and invasion of epithelial cells, and in evasion of immune clearance mechanisms. Gonococci shed during gonorrhoea make larger LOS. The higher M_ LOS made by MS1lmkC -- a strain used in human experimentation -- have polylactosamine structures. Polylactosaminylation explains the higher M_ molecules of this variant, but not those of others. Some serum resistant (ser_) gonococcal strains extend the LOS _ chain to form an _-lactose that is parallel to the _-lactose of the a chain, and meningococci can extend the _ chain. We are structuring higher M_ LOS made by clinical isolates: LOS made by ser_ strains, and LOS that appear to have higher order (Gb4 and P-1) globosyl oligosaccharides that are isobaric with paraglobosyl and gangliosyl LOS, respectively. We particularly want to know whether higher M_ LOS have parallel GSL-like antennae that could crosslink epithelial cell receptors. We will continue to rely on mass spectrometric techniques, but will also utilize high pH anion exchange chromatographic analyses. We know little about the lipoidal moieties of gonococcal LOS. This information is needed because the lipoidal moiety influences the conformation of the glycose moiety in ways that affect the latter's ability to bind glycoproteins, including antibodies. Available structural information from degraded LOS leaves unexplored the known O-acyl lipoidal moiety heterogeneity. We will profile gonococcal lipoidal moiety heterogeneity among strains, and perform more complete structural analysis on the lipoidal groups from select strains. Mabs have been used extensively in studies of gonococcal pathogenesis as surrogates for glycose structures. However, we do not have mAbs that discriminate among known glycose structures, much less for those that have yet to be found. We plan to expand our library of mAbs to include additional specificities. These mAbs will be necessary for complete studies of the role of LOS in pathogenesis.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。本项目继续研究低聚肌醇(LOS)模拟人鞘糖脂(GSL)如何使淋病奈瑟菌传播,以找到预防方法。LOW是外膜糖脂,具有由近端基底区和三个短的远端链(称为_,_和_)组成的糖部分。多链寡糖与乳糖(Lac-R)、球糖(P_(Gb 3)和P1)、副球糖(乳糖-N-新四糖(LNnT))和神经节糖(GalNAc_1-LNnT)系列GSL的结构相同。LOS参与上皮细胞的附着和侵袭,以及免疫清除机制的逃避。淋病时淋球菌脱落使LOS增大。由MS 1 lmkC--一种用于人体实验的菌株--产生的更高的M_ LOS具有聚乳糖胺结构。聚乳糖胺化解释了这种变体的较高M_分子,但不是其他变体的M_分子。一些血清抗性淋球菌菌株延伸LOS链形成与α链的α-乳糖平行的α-乳糖,脑膜炎球菌可以延伸α-乳糖链。 我们正在构建由临床分离株产生的更高M_ LOS:由ser_菌株产生的LOS,以及似乎具有分别与副糖基和神经节糖基LOS同量异序的更高阶(Gb 4和P-1)糖基寡糖的LOS。我们特别想知道是否更高的M_ LOS具有平行的GSL样触角,可以交联上皮细胞受体。我们将继续依靠质谱技术,但也将利用高pH阴离子交换色谱分析。 我们对淋球菌LOS的类脂部分知之甚少。需要该信息是因为类脂部分以影响糖部分结合糖蛋白(包括抗体)的能力的方式影响糖部分的构象。从降解LOS获得的结构信息未探索已知的O-酰基类脂部分的异质性。我们将描述淋球菌类脂部分菌株之间的异质性,并进行更完整的类脂基团从选择菌株的结构分析。 单克隆抗体已被广泛用于淋球菌发病机制的研究作为替代物的葡萄糖结构。然而,我们还没有能够区分已知糖结构的单克隆抗体,更不用说那些尚未发现的结构了。我们计划扩大我们的单克隆抗体库,以包括更多的特异性。这些单克隆抗体将是必要的LOS在发病机制中的作用的完整的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN McLeod GRIFFISS其他文献
JOHN McLeod GRIFFISS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN McLeod GRIFFISS', 18)}}的其他基金
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
传染病治疗的 I 期临床试验单位
- 批准号:
8335319 - 财政年份:2011
- 资助金额:
$ 0.09万 - 项目类别:
PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES
传染病治疗的 I 期临床试验装置
- 批准号:
8340145 - 财政年份:2011
- 资助金额:
$ 0.09万 - 项目类别:
PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES
传染病治疗的 I 期临床试验装置
- 批准号:
8340147 - 财政年份:2011
- 资助金额:
$ 0.09万 - 项目类别:
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
传染病治疗的 I 期临床试验单位
- 批准号:
8335318 - 财政年份:2011
- 资助金额:
$ 0.09万 - 项目类别:
PHASE I CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES
传染病治疗的 I 期临床试验装置
- 批准号:
8340149 - 财政年份:2011
- 资助金额:
$ 0.09万 - 项目类别:
Risk Factors and Susceptibility in Gonococcal Infection
淋球菌感染的危险因素和易感性
- 批准号:
8051393 - 财政年份:2010
- 资助金额:
$ 0.09万 - 项目类别:
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
传染病治疗的 I 期临床试验单位
- 批准号:
8656603 - 财政年份:2008
- 资助金额:
$ 0.09万 - 项目类别:
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
传染病治疗的 I 期临床试验单位
- 批准号:
8844892 - 财政年份:2008
- 资助金额:
$ 0.09万 - 项目类别:
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
传染病治疗的 I 期临床试验单位
- 批准号:
8844894 - 财政年份:2008
- 资助金额:
$ 0.09万 - 项目类别:
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
传染病治疗的 I 期临床试验单位
- 批准号:
8441449 - 财政年份:2008
- 资助金额:
$ 0.09万 - 项目类别:
相似海外基金
Development of a model of Gonococcal conjunctivitis for vaccine evaluations
开发用于疫苗评估的淋菌性结膜炎模型
- 批准号:
10740430 - 财政年份:2023
- 资助金额:
$ 0.09万 - 项目类别:
Mapping Protein Interaction Networks Essential for Gonococcal Pathogenesis
绘制淋球菌发病机制所必需的蛋白质相互作用网络
- 批准号:
10401945 - 财政年份:2021
- 资助金额:
$ 0.09万 - 项目类别:
Mapping Protein Interaction Networks Essential for Gonococcal Pathogenesis
绘制淋球菌发病机制所必需的蛋白质相互作用网络
- 批准号:
10814526 - 财政年份:2021
- 资助金额:
$ 0.09万 - 项目类别:
Acquisition of gonococcal denitrification apparatus in the Neisseria meningitidis urethritis clade
脑膜炎奈瑟菌尿道炎分支中淋菌反硝化装置的获得
- 批准号:
10317302 - 财政年份:2021
- 资助金额:
$ 0.09万 - 项目类别:
Gonococcal peptide vaccine candidate display using HPV virus-like particles
使用 HPV 病毒样颗粒展示候选淋球菌肽疫苗
- 批准号:
10390991 - 财政年份:2021
- 资助金额:
$ 0.09万 - 项目类别:
Acquisition of gonococcal denitrification apparatus in the Neisseria meningitidis urethritis clade
脑膜炎奈瑟菌尿道炎分支中淋菌反硝化装置的获得
- 批准号:
10448441 - 财政年份:2021
- 资助金额:
$ 0.09万 - 项目类别:
Gonococcal vaccine development guided by a cross-protective meningococcal vaccine
以交叉保护性脑膜炎球菌疫苗为指导的淋球菌疫苗开发
- 批准号:
nhmrc : 2002182 - 财政年份:2021
- 资助金额:
$ 0.09万 - 项目类别:
Ideas Grants
MOLECULAR BASIS OF PILUS-MEDIATED GONOCOCCAL ADHESION
菌毛介导的淋球菌粘附的分子基础
- 批准号:
10363679 - 财政年份:2021
- 资助金额:
$ 0.09万 - 项目类别:
Targeting the functions of the gonococcal Type lV pilus
针对 IV 型淋球菌菌毛的功能
- 批准号:
10663812 - 财政年份:2020
- 资助金额:
$ 0.09万 - 项目类别:
Complement-independent role of C4 binding protein in gonococcal survival from human neutrophils
C4 结合蛋白在人中性粒细胞淋球菌存活中的补体独立作用
- 批准号:
10155876 - 财政年份:2020
- 资助金额:
$ 0.09万 - 项目类别: